An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects.

Trial Profile

An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Retigabine (Primary)
  • Indications Epilepsy; Postherpetic neuralgia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 30 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 30 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top